Spatial Biology CRO Flagship Biosciences Completes The Acquisition Of Pharma Services Business

Flagship's offering of biomarker and analytics services has expanded due to the acquisition.

Fremont, CA: Flagship Biosciences, founded in 2009 and located in Broomfield, Colorado, is a technology-driven tissue analysis services firm that provides the most accurate and insightful data. Using the power of AI and a consultative approach, they are redefining tissue analysis to better drug development and diagnostics. Its services and technology greatly boost the data and interpretation provided by traditional pathology methods, decreasing the unpredictability associated with standard tissue assessments and providing fresh insights into tissue analysis findings. Every customer receives competent scientific consultation. The team analyses findings to contextualize tissue biology and determine the best path to achievement.

Interpace Pharma Products ("IPS"), a branch of Interpace Biosciences and supplier of cytogenetic, molecular pathology, & genomic profiling solutions, has been acquired by Flagship Biosciences, Inc. This acquisition followed Ampersand Capital Partners, BroadOak Capital Partners, and Research Corporation Technologies' growth equity investment in Flagship. The strategic merger of Flagship and IPS creates a comprehensive portfolio of biomarker lab and analytic services to drive precision treatment development and a state-of-the-art laboratory in Research Triangle Park, North Carolina.

Flagship Biosciences provides cutting-edge spatial biology services powered by its patented AI image analysis tech, which improves tissue-based pathology accuracy by delivering thousands of measurements on every cell and enabling the discovery of biomarkers that would otherwise get missed using traditional histology methods. 

Flagship's team of pathologists and regulatory strategy experts provides sophisticated end-to-end biomarker & analytics services to assist drug trials, biomarker development, and clinical diagnostics. They also provide direction in the development of diagnostic techniques.

Flagship Biosciences will combine IPS technology and services to assist all phases of clinical trials and diagnostic research in immuno-oncology, hematological, solid tumors, and several non-oncology sectors to serve their biopharma and diagnostics clients better. The extended services portfolio at Flagship Biosciences will now include sophisticated molecular biomarker solutions, flow cytometry, cytogenetics, genomics, and bioinformatics solutions. New genomic profiling tools will improve biomarker characterization and patient classification for clinical trials and therapy selection.

"By combining these organizations, we create a single-source provider offering a larger range of biomarker and analytics services while maintaining and expanding the proven expertise of each laboratory," said Trevor Johnson, CEO at Flagship Biosciences. "This will allow our customers to gain deeper insights into their clinical projects through multiple biomarker testing paradigms with cohesive data and analytical capabilities, managed in a simplified project workflow."